Intensive care of patients with HIV infection: HAART warming improvement but beware of future HAART (and heart) attacks

Chest

Volumn 125, Issue 5, 2004, Pages 1602-1604

  Morris, Alison ^a,b   Huang, Laurence ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; GLUCOSE INTOLERANCE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; PNEUMOCYSTIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SURVIVAL; VIRUS RESISTANCE;

EID: 2442555775     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.5.1602     Document Type: Editorial

References (15)

1. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommandations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-235
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860
3. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretiwiral therapy. Clin Infect Dis 2000; 30(Suppl 1):S5-S14
4. Wachter RM, Luce JM, Hopewell PC. Critical care of patients with AIDS. JAMA 1992; 267:541-547
5. Wachter RM, Luce JM, Turner J, et al. Intensive care of patients with the acquired immunodeficiency syndrome: outcome and changing patterns of utilization. Am Rev Respir Dis 1986; 134:891-896
6. Wachter RM, Russi MB, Bloch DA, et al. Pneumocystis carinii pneumonia and respiratory failure in AIDS: improved outcomes and increased use of intensive care units. Am Rev Respir Dis 1991; 143:251-256
7. Nickas G, Wachter RM. Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 2000; 160:541-547
8. Nuesch R, Geigy N, Schaedler E, et al. Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21:684-687
9. Morris A, Creasman J, Turner J, et al. Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 166:262-267
10. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430
11. Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164:847-851
12. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia. Lancet 1999; 354:1347-1351
13. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182:551-557
14. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis 2001; 183:819-822
15. Huang L, Morris AM, Beard CB. Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation. J Eukaryot Microbiol 2001; Suppl:180S-181S